Samantha MaWhinney
Concepts (510)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 87 | 2025 | 2898 | 4.480 |
Why?
| | Anti-HIV Agents | 40 | 2025 | 817 | 3.760 |
Why?
| | Adenine | 16 | 2025 | 293 | 2.030 |
Why?
| | Emtricitabine | 16 | 2025 | 196 | 2.010 |
Why?
| | Tenofovir | 18 | 2025 | 268 | 1.820 |
Why?
| | Organophosphates | 13 | 2025 | 152 | 1.760 |
Why?
| | Acquired Immunodeficiency Syndrome | 10 | 2023 | 232 | 1.570 |
Why?
| | HIV-1 | 31 | 2021 | 866 | 1.490 |
Why?
| | Dried Blood Spot Testing | 9 | 2024 | 115 | 1.400 |
Why?
| | Patient Dropouts | 3 | 2025 | 62 | 1.120 |
Why?
| | Pre-Exposure Prophylaxis | 8 | 2025 | 224 | 0.870 |
Why?
| | Medication Adherence | 12 | 2025 | 489 | 0.870 |
Why?
| | Viral Load | 20 | 2022 | 489 | 0.650 |
Why?
| | Directly Observed Therapy | 1 | 2017 | 17 | 0.550 |
Why?
| | Middle Aged | 68 | 2025 | 33226 | 0.510 |
Why?
| | Adult | 64 | 2025 | 37715 | 0.490 |
Why?
| | Anti-Retroviral Agents | 5 | 2019 | 240 | 0.480 |
Why?
| | Humans | 129 | 2025 | 136965 | 0.480 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 1027 | 0.460 |
Why?
| | Leukocytes, Mononuclear | 9 | 2021 | 561 | 0.460 |
Why?
| | Aging | 9 | 2023 | 1849 | 0.460 |
Why?
| | Male | 81 | 2025 | 67386 | 0.440 |
Why?
| | Zidovudine | 3 | 2012 | 77 | 0.420 |
Why?
| | Lamivudine | 3 | 2012 | 63 | 0.420 |
Why?
| | Female | 80 | 2025 | 73002 | 0.410 |
Why?
| | Unsafe Sex | 2 | 2012 | 62 | 0.410 |
Why?
| | Viremia | 6 | 2022 | 148 | 0.410 |
Why?
| | Cytochrome P-450 CYP3A | 2 | 2012 | 88 | 0.390 |
Why?
| | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 2 | 2025 | 19 | 0.380 |
Why?
| | CD8-Positive T-Lymphocytes | 9 | 2018 | 907 | 0.370 |
Why?
| | T-Lymphocytes, Cytotoxic | 6 | 2014 | 171 | 0.370 |
Why?
| | Sofosbuvir | 4 | 2022 | 66 | 0.360 |
Why?
| | Oligopeptides | 2 | 2012 | 269 | 0.360 |
Why?
| | Exercise | 6 | 2022 | 2064 | 0.340 |
Why?
| | Atazanavir Sulfate | 4 | 2016 | 43 | 0.340 |
Why?
| | Models, Statistical | 5 | 2022 | 662 | 0.330 |
Why?
| | Sustained Virologic Response | 3 | 2019 | 43 | 0.330 |
Why?
| | Prospective Studies | 23 | 2022 | 7512 | 0.330 |
Why?
| | HIV Integrase Inhibitors | 2 | 2024 | 69 | 0.330 |
Why?
| | Receptors, CCR5 | 6 | 2013 | 56 | 0.330 |
Why?
| | Mobile Applications | 2 | 2022 | 178 | 0.320 |
Why?
| | CD4-Positive T-Lymphocytes | 9 | 2016 | 1083 | 0.320 |
Why?
| | Dideoxynucleotides | 2 | 2012 | 14 | 0.320 |
Why?
| | Cytidine Triphosphate | 2 | 2012 | 16 | 0.320 |
Why?
| | Pyridines | 2 | 2012 | 497 | 0.310 |
Why?
| | Phosphorous Acids | 2 | 2019 | 15 | 0.310 |
Why?
| | Emigrants and Immigrants | 1 | 2012 | 142 | 0.310 |
Why?
| | Levonorgestrel | 2 | 2012 | 36 | 0.300 |
Why?
| | Frailty | 2 | 2022 | 170 | 0.290 |
Why?
| | Antiviral Agents | 3 | 2019 | 757 | 0.290 |
Why?
| | Sarcoma, Kaposi | 3 | 2022 | 79 | 0.280 |
Why?
| | Antiretroviral Therapy, Highly Active | 8 | 2019 | 276 | 0.280 |
Why?
| | Longitudinal Studies | 7 | 2025 | 2851 | 0.280 |
Why?
| | Quality of Life | 7 | 2023 | 2899 | 0.270 |
Why?
| | Gonadal Steroid Hormones | 1 | 2008 | 139 | 0.260 |
Why?
| | Lymphocyte Activation | 10 | 2018 | 1134 | 0.260 |
Why?
| | Prion Diseases | 1 | 2006 | 16 | 0.260 |
Why?
| | Exercise Therapy | 3 | 2020 | 440 | 0.260 |
Why?
| | Deoxyadenine Nucleotides | 2 | 2016 | 16 | 0.260 |
Why?
| | Deoxycytosine Nucleotides | 2 | 2016 | 13 | 0.260 |
Why?
| | Creutzfeldt-Jakob Syndrome | 1 | 2006 | 19 | 0.260 |
Why?
| | Wasting Disease, Chronic | 1 | 2006 | 26 | 0.250 |
Why?
| | Coronary Artery Bypass | 8 | 2004 | 230 | 0.250 |
Why?
| | Inflammation | 5 | 2021 | 2831 | 0.250 |
Why?
| | Lymph Nodes | 6 | 2017 | 483 | 0.250 |
Why?
| | Aged | 26 | 2023 | 23803 | 0.240 |
Why?
| | Data Interpretation, Statistical | 2 | 2025 | 357 | 0.240 |
Why?
| | Young Adult | 17 | 2025 | 13218 | 0.240 |
Why?
| | Gene Expression | 2 | 2014 | 1480 | 0.240 |
Why?
| | Simian Immunodeficiency Virus | 2 | 2016 | 89 | 0.230 |
Why?
| | CD4 Lymphocyte Count | 11 | 2020 | 274 | 0.230 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 2 | 2016 | 86 | 0.230 |
Why?
| | Body Composition | 4 | 2024 | 690 | 0.230 |
Why?
| | Bias | 2 | 2025 | 222 | 0.220 |
Why?
| | Contraceptives, Postcoital | 1 | 2004 | 2 | 0.220 |
Why?
| | HIV | 4 | 2019 | 242 | 0.220 |
Why?
| | Cross-Over Studies | 4 | 2020 | 547 | 0.220 |
Why?
| | Computer Simulation | 4 | 2025 | 982 | 0.210 |
Why?
| | Population Surveillance | 3 | 2002 | 487 | 0.210 |
Why?
| | Advance Care Planning | 2 | 2021 | 221 | 0.210 |
Why?
| | Cytokines | 3 | 2009 | 2070 | 0.210 |
Why?
| | Cohort Studies | 8 | 2023 | 5688 | 0.200 |
Why?
| | Physical Fitness | 2 | 2015 | 208 | 0.200 |
Why?
| | Lipopolysaccharide Receptors | 2 | 2021 | 89 | 0.200 |
Why?
| | HIV Integrase | 1 | 2024 | 69 | 0.200 |
Why?
| | Fluorenes | 2 | 2020 | 45 | 0.190 |
Why?
| | HIV Seropositivity | 3 | 2012 | 124 | 0.190 |
Why?
| | Drug Resistance, Viral | 2 | 2019 | 117 | 0.180 |
Why?
| | High-Intensity Interval Training | 1 | 2022 | 25 | 0.180 |
Why?
| | Telerehabilitation | 1 | 2022 | 38 | 0.180 |
Why?
| | Cell Phone | 1 | 2022 | 76 | 0.180 |
Why?
| | Lymphoid Tissue | 3 | 2008 | 76 | 0.180 |
Why?
| | Benzimidazoles | 2 | 2020 | 173 | 0.180 |
Why?
| | RNA, Viral | 9 | 2014 | 682 | 0.180 |
Why?
| | Hepatitis C | 2 | 2022 | 272 | 0.180 |
Why?
| | Alanine | 4 | 2024 | 151 | 0.180 |
Why?
| | Hair | 2 | 2018 | 92 | 0.170 |
Why?
| | Protease Inhibitors | 2 | 2020 | 108 | 0.170 |
Why?
| | Fees and Charges | 1 | 2000 | 10 | 0.170 |
Why?
| | Ritonavir | 2 | 2012 | 75 | 0.170 |
Why?
| | Polyphosphates | 4 | 2022 | 42 | 0.170 |
Why?
| | Hyperlipidemias | 1 | 2021 | 123 | 0.160 |
Why?
| | Interleukin-10 | 2 | 2021 | 299 | 0.160 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 116 | 0.160 |
Why?
| | Advance Directives | 1 | 2021 | 81 | 0.160 |
Why?
| | Research Design | 2 | 2025 | 1114 | 0.160 |
Why?
| | Costs and Cost Analysis | 1 | 2000 | 208 | 0.160 |
Why?
| | ADP-ribosyl Cyclase 1 | 4 | 2013 | 39 | 0.160 |
Why?
| | Biomarkers | 7 | 2021 | 4095 | 0.150 |
Why?
| | Thymine Nucleotides | 2 | 2016 | 17 | 0.150 |
Why?
| | Myocardial Ischemia | 1 | 2000 | 255 | 0.150 |
Why?
| | Cytomegalovirus Infections | 2 | 2015 | 191 | 0.150 |
Why?
| | Hepatitis C, Chronic | 2 | 2019 | 164 | 0.140 |
Why?
| | Blood Chemical Analysis | 4 | 2019 | 106 | 0.140 |
Why?
| | Simeprevir | 1 | 2018 | 10 | 0.140 |
Why?
| | Colorado | 7 | 2022 | 4542 | 0.140 |
Why?
| | Raltegravir Potassium | 2 | 2015 | 17 | 0.140 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2018 | 33 | 0.140 |
Why?
| | Transgender Persons | 1 | 2021 | 188 | 0.140 |
Why?
| | Virus Replication | 5 | 2017 | 518 | 0.140 |
Why?
| | Epitopes, T-Lymphocyte | 4 | 2008 | 182 | 0.140 |
Why?
| | Viral Tropism | 1 | 2017 | 33 | 0.140 |
Why?
| | Pharmacogenetics | 2 | 2016 | 165 | 0.130 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2007 | 126 | 0.130 |
Why?
| | Length of Stay | 4 | 2000 | 1192 | 0.130 |
Why?
| | Sleep Wake Disorders | 1 | 2020 | 300 | 0.130 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2017 | 134 | 0.130 |
Why?
| | Pyrophosphatases | 1 | 2016 | 28 | 0.130 |
Why?
| | Deoxyguanine Nucleotides | 1 | 2016 | 12 | 0.130 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 451 | 0.130 |
Why?
| | Genitalia | 1 | 2016 | 32 | 0.130 |
Why?
| | Motor Activity | 4 | 2015 | 714 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2019 | 504 | 0.130 |
Why?
| | Germinal Center | 1 | 2016 | 62 | 0.130 |
Why?
| | Vaccines, DNA | 2 | 2008 | 32 | 0.120 |
Why?
| | Ribavirin | 1 | 2016 | 94 | 0.120 |
Why?
| | HIV Protease Inhibitors | 2 | 2016 | 69 | 0.120 |
Why?
| | AIDS Vaccines | 2 | 2008 | 53 | 0.120 |
Why?
| | Purines | 1 | 2016 | 176 | 0.120 |
Why?
| | Muscle Strength | 1 | 2018 | 320 | 0.120 |
Why?
| | Risk Factors | 11 | 2021 | 10363 | 0.120 |
Why?
| | Disease Transmission, Infectious | 2 | 2018 | 64 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 4 | 2015 | 415 | 0.120 |
Why?
| | Biometry | 2 | 2011 | 68 | 0.120 |
Why?
| | HLA-DR Antigens | 3 | 2012 | 226 | 0.120 |
Why?
| | Case-Control Studies | 7 | 2016 | 3556 | 0.120 |
Why?
| | Genitalia, Female | 1 | 2015 | 38 | 0.120 |
Why?
| | Rectum | 1 | 2016 | 185 | 0.110 |
Why?
| | Antibodies, Viral | 3 | 2015 | 646 | 0.110 |
Why?
| | Mental Health Services | 1 | 2019 | 429 | 0.110 |
Why?
| | Organophosphonates | 1 | 2015 | 95 | 0.110 |
Why?
| | Linear Models | 4 | 2020 | 857 | 0.110 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2017 | 384 | 0.110 |
Why?
| | Probability | 2 | 2011 | 306 | 0.110 |
Why?
| | Calcifediol | 1 | 2014 | 33 | 0.110 |
Why?
| | Calcitriol | 1 | 2014 | 59 | 0.110 |
Why?
| | Sexual and Gender Minorities | 1 | 2017 | 225 | 0.110 |
Why?
| | Deoxycytidine | 1 | 2015 | 186 | 0.110 |
Why?
| | Immunoglobulin Variable Region | 1 | 2014 | 79 | 0.100 |
Why?
| | Disease Progression | 4 | 2015 | 2708 | 0.100 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2014 | 81 | 0.100 |
Why?
| | Membrane Glycoproteins | 3 | 2013 | 496 | 0.100 |
Why?
| | Telemedicine | 1 | 2022 | 863 | 0.100 |
Why?
| | Patient Compliance | 1 | 2017 | 591 | 0.100 |
Why?
| | Multivariate Analysis | 8 | 2007 | 1484 | 0.100 |
Why?
| | Decision Making | 1 | 2021 | 935 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2021 | 698 | 0.100 |
Why?
| | Adolescent | 14 | 2020 | 21471 | 0.100 |
Why?
| | Microbiota | 1 | 2021 | 759 | 0.100 |
Why?
| | Chromatography, Liquid | 3 | 2019 | 437 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2015 | 236 | 0.100 |
Why?
| | Immunoglobulin G | 2 | 2015 | 892 | 0.100 |
Why?
| | Time Factors | 8 | 2019 | 6786 | 0.100 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 1994 | 185 | 0.100 |
Why?
| | Spleen | 1 | 2014 | 514 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2004 | 2080 | 0.100 |
Why?
| | Hepatitis A Vaccines | 1 | 2012 | 15 | 0.090 |
Why?
| | Dendritic Cells | 2 | 2008 | 483 | 0.090 |
Why?
| | Hepatitis A | 1 | 2012 | 25 | 0.090 |
Why?
| | Benzoxazines | 1 | 2012 | 31 | 0.090 |
Why?
| | Numerical Analysis, Computer-Assisted | 2 | 2002 | 18 | 0.090 |
Why?
| | Cervix Uteri | 1 | 2012 | 49 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1056 | 0.090 |
Why?
| | Sarcopenia | 1 | 2013 | 79 | 0.090 |
Why?
| | Tandem Mass Spectrometry | 3 | 2019 | 538 | 0.090 |
Why?
| | Cell Movement | 3 | 2016 | 964 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 254 | 0.090 |
Why?
| | Contraceptive Agents | 1 | 2012 | 66 | 0.090 |
Why?
| | Haplotypes | 2 | 2012 | 495 | 0.090 |
Why?
| | Benchmarking | 2 | 2024 | 184 | 0.090 |
Why?
| | Muscle, Skeletal | 1 | 2021 | 1712 | 0.090 |
Why?
| | Polymorphism, Genetic | 2 | 2016 | 634 | 0.090 |
Why?
| | B-Lymphocytes | 1 | 2016 | 845 | 0.090 |
Why?
| | CD4 Antigens | 1 | 2011 | 140 | 0.090 |
Why?
| | Contraceptive Agents, Female | 1 | 2012 | 78 | 0.090 |
Why?
| | Retrospective Studies | 9 | 2021 | 15536 | 0.090 |
Why?
| | Mental Disorders | 1 | 2019 | 1089 | 0.090 |
Why?
| | Sex Factors | 5 | 2018 | 2060 | 0.090 |
Why?
| | HIV Seronegativity | 1 | 2010 | 28 | 0.090 |
Why?
| | Antacids | 1 | 2010 | 15 | 0.090 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1903 | 0.080 |
Why?
| | Pyrrolidinones | 1 | 2010 | 29 | 0.080 |
Why?
| | Drug Monitoring | 2 | 2022 | 208 | 0.080 |
Why?
| | Osteoporosis | 1 | 2013 | 241 | 0.080 |
Why?
| | Accidental Falls | 1 | 2012 | 193 | 0.080 |
Why?
| | Herpesvirus 8, Human | 2 | 2000 | 65 | 0.080 |
Why?
| | Postmenopause | 1 | 2012 | 367 | 0.080 |
Why?
| | Diphosphates | 2 | 2021 | 19 | 0.080 |
Why?
| | Predictive Value of Tests | 4 | 2019 | 1999 | 0.080 |
Why?
| | Cross-Sectional Studies | 8 | 2019 | 5530 | 0.080 |
Why?
| | Cytomegalovirus | 2 | 2015 | 157 | 0.080 |
Why?
| | Zimbabwe | 3 | 2022 | 58 | 0.080 |
Why?
| | Drug Interactions | 3 | 2019 | 400 | 0.070 |
Why?
| | Complementarity Determining Regions | 2 | 2014 | 51 | 0.070 |
Why?
| | Cytotoxicity Tests, Immunologic | 3 | 2003 | 39 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2016 | 2142 | 0.070 |
Why?
| | Molecular Sequence Data | 3 | 2009 | 2900 | 0.070 |
Why?
| | Demography | 2 | 2022 | 295 | 0.070 |
Why?
| | Sequence Analysis, DNA | 2 | 2009 | 824 | 0.070 |
Why?
| | Lung Diseases | 1 | 2015 | 767 | 0.070 |
Why?
| | Hepacivirus | 2 | 2022 | 260 | 0.070 |
Why?
| | Mutation | 2 | 2014 | 3975 | 0.070 |
Why?
| | Healthy Volunteers | 2 | 2018 | 202 | 0.070 |
Why?
| | Plasma | 1 | 2009 | 215 | 0.070 |
Why?
| | Interleukin-12 | 2 | 1998 | 120 | 0.070 |
Why?
| | Hospitals, Veterans | 3 | 2004 | 254 | 0.060 |
Why?
| | Managed Care Programs | 1 | 2007 | 141 | 0.060 |
Why?
| | Deer | 1 | 2006 | 32 | 0.060 |
Why?
| | Adipocytes | 1 | 2008 | 226 | 0.060 |
Why?
| | Interferon-gamma | 3 | 2008 | 782 | 0.060 |
Why?
| | Comorbidity | 3 | 2019 | 1626 | 0.060 |
Why?
| | Treatment Outcome | 10 | 2018 | 10664 | 0.060 |
Why?
| | Self Report | 2 | 2021 | 836 | 0.060 |
Why?
| | Therapeutic Equivalency | 2 | 2018 | 30 | 0.060 |
Why?
| | Physicians, Family | 1 | 2007 | 194 | 0.060 |
Why?
| | Preventive Health Services | 1 | 2007 | 153 | 0.060 |
Why?
| | Interleukin-6 | 2 | 2021 | 781 | 0.060 |
Why?
| | Kenya | 1 | 2025 | 119 | 0.060 |
Why?
| | Macaca mulatta | 2 | 2016 | 182 | 0.060 |
Why?
| | Flow Cytometry | 4 | 2015 | 1189 | 0.060 |
Why?
| | Immunoenzyme Techniques | 1 | 2005 | 206 | 0.060 |
Why?
| | T-Lymphocytes | 3 | 2005 | 1975 | 0.060 |
Why?
| | Incidence | 4 | 2012 | 2793 | 0.060 |
Why?
| | Area Under Curve | 2 | 2018 | 303 | 0.060 |
Why?
| | Licensure, Pharmacy | 1 | 2004 | 1 | 0.050 |
Why?
| | Northern Ireland | 1 | 2004 | 7 | 0.050 |
Why?
| | Immunologic Memory | 2 | 2009 | 353 | 0.050 |
Why?
| | New York City | 2 | 1994 | 85 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2016 | 248 | 0.050 |
Why?
| | Odds Ratio | 3 | 2014 | 1071 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 3 | 2015 | 382 | 0.050 |
Why?
| | Pilot Projects | 3 | 2022 | 1730 | 0.050 |
Why?
| | Hospitalization | 3 | 2022 | 2182 | 0.050 |
Why?
| | Survival Analysis | 3 | 2015 | 1278 | 0.050 |
Why?
| | HIV Antibodies | 2 | 2014 | 61 | 0.050 |
Why?
| | Patient Satisfaction | 1 | 2007 | 671 | 0.050 |
Why?
| | Conserved Sequence | 1 | 2003 | 235 | 0.050 |
Why?
| | Ki-67 Antigen | 2 | 2017 | 108 | 0.050 |
Why?
| | Integrases | 1 | 2024 | 120 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2014 | 5812 | 0.050 |
Why?
| | Tablets | 1 | 2022 | 40 | 0.050 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2002 | 83 | 0.050 |
Why?
| | Creatinine | 3 | 2018 | 486 | 0.050 |
Why?
| | Cells, Cultured | 4 | 2017 | 4136 | 0.050 |
Why?
| | Quality of Health Care | 1 | 2007 | 648 | 0.050 |
Why?
| | Likelihood Functions | 3 | 2001 | 143 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 1022 | 0.050 |
Why?
| | Models, Biological | 2 | 2016 | 1780 | 0.050 |
Why?
| | Bayes Theorem | 2 | 2020 | 410 | 0.050 |
Why?
| | Drug Prescriptions | 1 | 2004 | 258 | 0.050 |
Why?
| | Habits | 1 | 2022 | 51 | 0.050 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2021 | 10 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2007 | 766 | 0.050 |
Why?
| | Angina Pectoris | 1 | 2001 | 63 | 0.050 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 41 | 0.040 |
Why?
| | Phenotype | 4 | 2016 | 3148 | 0.040 |
Why?
| | Citrate (si)-Synthase | 1 | 2021 | 60 | 0.040 |
Why?
| | Antigens, Viral | 3 | 2014 | 178 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 43 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 83 | 0.040 |
Why?
| | Mental Health | 2 | 2019 | 733 | 0.040 |
Why?
| | Diagnosis-Related Groups | 1 | 2000 | 31 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 335 | 0.040 |
Why?
| | Hand Strength | 1 | 2021 | 122 | 0.040 |
Why?
| | Hemarthrosis | 1 | 2000 | 21 | 0.040 |
Why?
| | HIV Antigens | 2 | 2015 | 18 | 0.040 |
Why?
| | Heart Valves | 1 | 2000 | 42 | 0.040 |
Why?
| | Death | 1 | 2021 | 118 | 0.040 |
Why?
| | Weight Gain | 1 | 2024 | 535 | 0.040 |
Why?
| | Actigraphy | 1 | 2020 | 115 | 0.040 |
Why?
| | Weight Loss | 2 | 2020 | 783 | 0.040 |
Why?
| | Communicable Diseases | 1 | 2002 | 161 | 0.040 |
Why?
| | Virus Diseases | 1 | 2002 | 212 | 0.040 |
Why?
| | Drug Combinations | 1 | 2020 | 341 | 0.040 |
Why?
| | Immunophenotyping | 3 | 2007 | 323 | 0.040 |
Why?
| | Superoxide Dismutase | 1 | 2021 | 351 | 0.040 |
Why?
| | Amino Acid Motifs | 2 | 2014 | 222 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 1999 | 56 | 0.040 |
Why?
| | Age Factors | 3 | 2000 | 3258 | 0.040 |
Why?
| | Regression Analysis | 2 | 2007 | 1007 | 0.040 |
Why?
| | Capsules | 1 | 2018 | 39 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 500 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2007 | 222 | 0.040 |
Why?
| | Herpesviridae Infections | 1 | 1999 | 146 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2022 | 965 | 0.040 |
Why?
| | Chemoprevention | 1 | 2018 | 93 | 0.040 |
Why?
| | Uganda | 1 | 2018 | 84 | 0.040 |
Why?
| | Drug Compounding | 1 | 2018 | 101 | 0.040 |
Why?
| | Chemistry Techniques, Analytical | 1 | 2018 | 22 | 0.040 |
Why?
| | Renal Insufficiency | 1 | 2000 | 160 | 0.040 |
Why?
| | Nanomedicine | 1 | 2018 | 45 | 0.040 |
Why?
| | Hemophilia A | 1 | 2000 | 139 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 107 | 0.040 |
Why?
| | Oxazines | 1 | 2018 | 30 | 0.040 |
Why?
| | Heart Diseases | 2 | 2000 | 325 | 0.030 |
Why?
| | Histoplasmosis | 1 | 1997 | 15 | 0.030 |
Why?
| | Severity of Illness Index | 3 | 2000 | 2809 | 0.030 |
Why?
| | Fluconazole | 1 | 1997 | 20 | 0.030 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2018 | 89 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2021 | 7559 | 0.030 |
Why?
| | Cardiology Service, Hospital | 1 | 1997 | 24 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 2021 | 549 | 0.030 |
Why?
| | Cause of Death | 1 | 2019 | 428 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2022 | 458 | 0.030 |
Why?
| | Palatine Tonsil | 1 | 2017 | 50 | 0.030 |
Why?
| | Internet | 1 | 2002 | 678 | 0.030 |
Why?
| | Inosine Triphosphate | 1 | 2016 | 2 | 0.030 |
Why?
| | Fatigue | 1 | 2019 | 337 | 0.030 |
Why?
| | Anemia, Hemolytic | 1 | 2016 | 20 | 0.030 |
Why?
| | Perforin | 1 | 2016 | 19 | 0.030 |
Why?
| | Genotype | 3 | 2012 | 1872 | 0.030 |
Why?
| | Clinical Studies as Topic | 1 | 2016 | 11 | 0.030 |
Why?
| | Antifungal Agents | 1 | 1997 | 132 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2000 | 581 | 0.030 |
Why?
| | Guanosine Triphosphate | 1 | 2016 | 90 | 0.030 |
Why?
| | Half-Life | 1 | 2016 | 143 | 0.030 |
Why?
| | Child | 7 | 2017 | 21760 | 0.030 |
Why?
| | Primary Health Care | 1 | 2007 | 1775 | 0.030 |
Why?
| | Lymphocyte Depletion | 1 | 2016 | 136 | 0.030 |
Why?
| | Prognosis | 2 | 2021 | 3931 | 0.030 |
Why?
| | Pyridones | 1 | 2018 | 170 | 0.030 |
Why?
| | Lung | 2 | 2022 | 4035 | 0.030 |
Why?
| | Machine Learning | 1 | 2021 | 513 | 0.030 |
Why?
| | Nucleotides | 1 | 2016 | 125 | 0.030 |
Why?
| | Peru | 1 | 2016 | 60 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 420 | 0.030 |
Why?
| | Eating | 1 | 1999 | 392 | 0.030 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 1998 | 174 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1229 | 0.030 |
Why?
| | Spermatozoa | 1 | 2016 | 94 | 0.030 |
Why?
| | United States | 6 | 2016 | 14945 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 1998 | 256 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1460 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2016 | 198 | 0.030 |
Why?
| | Clinical Protocols | 1 | 1997 | 265 | 0.030 |
Why?
| | Algorithms | 2 | 2011 | 1700 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 21 | 0.030 |
Why?
| | Piperazines | 1 | 2018 | 343 | 0.030 |
Why?
| | South Africa | 1 | 2016 | 226 | 0.030 |
Why?
| | Animals | 4 | 2016 | 36882 | 0.030 |
Why?
| | Receptors, CXCR4 | 2 | 2007 | 86 | 0.030 |
Why?
| | Drug Users | 1 | 2015 | 41 | 0.030 |
Why?
| | Receptors, CXCR5 | 1 | 2014 | 21 | 0.030 |
Why?
| | Receptors, CCR7 | 1 | 2014 | 32 | 0.030 |
Why?
| | Blood | 1 | 2015 | 108 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 727 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 749 | 0.030 |
Why?
| | Cathelicidins | 1 | 2014 | 41 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2016 | 481 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2012 | 1045 | 0.030 |
Why?
| | Mutation Rate | 1 | 2014 | 30 | 0.030 |
Why?
| | Child, Preschool | 4 | 2002 | 10952 | 0.030 |
Why?
| | Registries | 1 | 2022 | 2048 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 116 | 0.030 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2014 | 97 | 0.030 |
Why?
| | Aging, Premature | 1 | 2013 | 13 | 0.030 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 39 | 0.030 |
Why?
| | Body Fat Distribution | 1 | 2013 | 49 | 0.030 |
Why?
| | Kidney Failure, Chronic | 1 | 1999 | 569 | 0.020 |
Why?
| | Infant | 3 | 2002 | 9392 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 304 | 0.020 |
Why?
| | Energy Metabolism | 1 | 1999 | 919 | 0.020 |
Why?
| | Infant, Newborn | 2 | 1994 | 6051 | 0.020 |
Why?
| | Mothers | 1 | 1999 | 758 | 0.020 |
Why?
| | Frail Elderly | 1 | 2013 | 130 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2015 | 639 | 0.020 |
Why?
| | Muscles | 1 | 2013 | 327 | 0.020 |
Why?
| | Clone Cells | 2 | 2002 | 263 | 0.020 |
Why?
| | Cyclopropanes | 1 | 2012 | 67 | 0.020 |
Why?
| | Alkynes | 1 | 2012 | 57 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2011 | 24 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 1997 | 526 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 331 | 0.020 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2013 | 320 | 0.020 |
Why?
| | Bone and Bones | 1 | 2013 | 318 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2015 | 5048 | 0.020 |
Why?
| | Geography | 1 | 2011 | 202 | 0.020 |
Why?
| | Pregnancy Complications, Infectious | 1 | 1994 | 392 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2016 | 1096 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 347 | 0.020 |
Why?
| | Chi-Square Distribution | 2 | 2002 | 521 | 0.020 |
Why?
| | North America | 1 | 2011 | 308 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2001 | 2622 | 0.020 |
Why?
| | Interleukin-2 | 2 | 2003 | 449 | 0.020 |
Why?
| | Depression | 1 | 2019 | 1454 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2012 | 578 | 0.020 |
Why?
| | Bone Density | 1 | 2013 | 488 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2016 | 2456 | 0.020 |
Why?
| | Body Mass Index | 2 | 2013 | 2416 | 0.020 |
Why?
| | Postoperative Hemorrhage | 2 | 2000 | 83 | 0.020 |
Why?
| | United States Department of Veterans Affairs | 2 | 2004 | 680 | 0.020 |
Why?
| | DNA, Viral | 2 | 2000 | 367 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2000 | 3574 | 0.020 |
Why?
| | Respiratory Tract Diseases | 2 | 2000 | 180 | 0.020 |
Why?
| | Health Status | 2 | 2004 | 817 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1310 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2574 | 0.020 |
Why?
| | Personnel Turnover | 1 | 2007 | 38 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2007 | 147 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 506 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 861 | 0.020 |
Why?
| | Sweating | 1 | 2007 | 40 | 0.020 |
Why?
| | Risk Assessment | 3 | 2004 | 3446 | 0.020 |
Why?
| | Hospital Mortality | 2 | 2004 | 895 | 0.020 |
Why?
| | Gender Identity | 1 | 2007 | 124 | 0.020 |
Why?
| | Fever | 1 | 2007 | 304 | 0.010 |
Why?
| | Health Care Surveys | 1 | 2007 | 564 | 0.010 |
Why?
| | Obesity | 1 | 1999 | 3023 | 0.010 |
Why?
| | Selection Bias | 1 | 2005 | 37 | 0.010 |
Why?
| | DNA | 1 | 2012 | 1441 | 0.010 |
Why?
| | Quality Indicators, Health Care | 1 | 2007 | 306 | 0.010 |
Why?
| | Acute Disease | 1 | 2007 | 993 | 0.010 |
Why?
| | Base Sequence | 1 | 2008 | 2168 | 0.010 |
Why?
| | Cell Line | 2 | 2001 | 2855 | 0.010 |
Why?
| | Neoplasms | 1 | 2019 | 2698 | 0.010 |
Why?
| | HLA-A3 Antigen | 1 | 2003 | 6 | 0.010 |
Why?
| | HLA-B7 Antigen | 1 | 2003 | 7 | 0.010 |
Why?
| | HLA-A2 Antigen | 1 | 2003 | 48 | 0.010 |
Why?
| | Superantigens | 1 | 2003 | 69 | 0.010 |
Why?
| | Intraoperative Care | 1 | 2004 | 55 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 2003 | 125 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2003 | 144 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2008 | 1904 | 0.010 |
Why?
| | Virus Activation | 1 | 2003 | 85 | 0.010 |
Why?
| | Postoperative Period | 1 | 2004 | 338 | 0.010 |
Why?
| | B7-2 Antigen | 1 | 2002 | 28 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2003 | 189 | 0.010 |
Why?
| | Chronic Disease | 1 | 2009 | 1774 | 0.010 |
Why?
| | Morbidity | 1 | 2004 | 319 | 0.010 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2002 | 22 | 0.010 |
Why?
| | Hospital-Physician Relations | 1 | 2002 | 3 | 0.010 |
Why?
| | Parainfluenza Virus 3, Human | 1 | 2002 | 5 | 0.010 |
Why?
| | Community Medicine | 1 | 2002 | 6 | 0.010 |
Why?
| | Rotavirus | 1 | 2002 | 20 | 0.010 |
Why?
| | CD40 Antigens | 1 | 2002 | 88 | 0.010 |
Why?
| | Attitude to Computers | 1 | 2002 | 29 | 0.010 |
Why?
| | Sick Role | 1 | 2001 | 18 | 0.010 |
Why?
| | HIV Core Protein p24 | 1 | 2001 | 31 | 0.010 |
Why?
| | Immunity, Cellular | 1 | 2003 | 267 | 0.010 |
Why?
| | Pregnancy | 1 | 1994 | 6736 | 0.010 |
Why?
| | Streptococcus pyogenes | 1 | 2002 | 45 | 0.010 |
Why?
| | Preoperative Care | 1 | 2004 | 348 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 850 | 0.010 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2002 | 73 | 0.010 |
Why?
| | Health Services Research | 1 | 2004 | 406 | 0.010 |
Why?
| | Nonlinear Dynamics | 1 | 2001 | 88 | 0.010 |
Why?
| | Phosphorus Radioisotopes | 1 | 2000 | 27 | 0.010 |
Why?
| | Elbow | 1 | 2000 | 55 | 0.010 |
Why?
| | Community-Acquired Infections | 1 | 2002 | 171 | 0.010 |
Why?
| | Ankle | 1 | 2000 | 60 | 0.010 |
Why?
| | Antigens, CD | 1 | 2002 | 527 | 0.010 |
Why?
| | Knee | 1 | 2000 | 68 | 0.010 |
Why?
| | Hyperplasia | 1 | 2000 | 175 | 0.010 |
Why?
| | Hemophilia B | 1 | 2000 | 61 | 0.010 |
Why?
| | Forecasting | 1 | 2001 | 386 | 0.010 |
Why?
| | Synovial Membrane | 1 | 2000 | 116 | 0.010 |
Why?
| | Seasons | 1 | 2002 | 541 | 0.010 |
Why?
| | Calorimetry, Indirect | 1 | 1999 | 84 | 0.010 |
Why?
| | Diet Records | 1 | 1999 | 83 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1998 | 51 | 0.010 |
Why?
| | Fathers | 1 | 1999 | 51 | 0.010 |
Why?
| | Cost Control | 1 | 1998 | 37 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2003 | 2156 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2139 | 0.010 |
Why?
| | Activities of Daily Living | 1 | 2001 | 415 | 0.010 |
Why?
| | Anthropometry | 1 | 1999 | 213 | 0.010 |
Why?
| | Erythrocyte Transfusion | 1 | 2000 | 197 | 0.010 |
Why?
| | Absorptiometry, Photon | 1 | 1999 | 264 | 0.010 |
Why?
| | Radiography | 1 | 2000 | 814 | 0.010 |
Why?
| | Puberty | 1 | 1999 | 152 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2000 | 1301 | 0.010 |
Why?
| | Streptokinase | 1 | 1996 | 10 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2005 | 3266 | 0.010 |
Why?
| | Phytohemagglutinins | 1 | 1996 | 28 | 0.010 |
Why?
| | Tetanus Toxoid | 1 | 1996 | 37 | 0.010 |
Why?
| | Cell Division | 1 | 1998 | 789 | 0.010 |
Why?
| | Candida | 1 | 1996 | 37 | 0.010 |
Why?
| | Postoperative Care | 1 | 1998 | 255 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 1997 | 662 | 0.010 |
Why?
| | Antigens, Bacterial | 1 | 1996 | 127 | 0.010 |
Why?
| | Exercise Test | 1 | 1999 | 617 | 0.010 |
Why?
| | Survival Rate | 1 | 2000 | 1882 | 0.010 |
Why?
| | Logistic Models | 1 | 2000 | 2066 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 1999 | 705 | 0.010 |
Why?
| | Adipose Tissue | 1 | 1999 | 642 | 0.010 |
Why?
| | Patient Selection | 1 | 1997 | 685 | 0.010 |
Why?
| | Databases, Factual | 1 | 1999 | 1367 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1343 | 0.010 |
Why?
| | Prevalence | 1 | 1999 | 2732 | 0.010 |
Why?
| | Mice | 1 | 2003 | 17705 | 0.000 |
Why?
|
|
MaWhinney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|